Search Result

Results for "

pd-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (188) Akt (2) Apoptosis (8) Aryl Hydrocarbon Receptor (1) AUTACs (1) Autophagy (1) Btk (1) CD3 (1) CTLA-4 (4) CXCR (1) Drug-Linker Conjugates for ADC (1) EGFR (1) HBV (3) HDAC (2) Histone Demethylase (1) IFNAR (1) Interleukin Related (2) Itk (1) LAG-3 (1) Ligands for Target Protein for PROTAC (1) NAMPT (1) NF-κB (2) PARP (2) PI3K (1) PROTACs (1) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) VEGFR (1) VISTA (1)
By Research Areas:	Cancer (168) Infection (7) Inflammation/Immunology (55) Metabolic Disease (1)
Click Chemistry:	DBCO (1) Azide (1)

188

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101058A

PD1-PDL1-IN 1 TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator ^[1].

HY-134886

PD-1-IN-24	PD-1/PD-L1	Cancer
PD-1-IN-24 (compound 1) is an orally active *PD-1* inhibitor ^[1].

HY-101097

PD-1-IN-17	PD-1/PD-L1	Cancer
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM ^[1].

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-101058

PD1-PDL1-IN 1	PD-1/PD-L1	Inflammation/Immunology
PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator ^[1].

HY-101098

PD-1-IN-18	PD-1/PD-L1	Inflammation/Immunology
PD-1-IN-18 is a *PD1* signaling pathway inhibitor, which acts as an immunomodulator.

HY-157569

PD1-PDL1-IN 2	PD-1/PD-L1	Cancer
PD1-PDL1-IN 2 (ZE132) is a potent and selective *PD-1/PD-L1* inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β ^[1].

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM ^[1].

HY-101093B

PD-1-IN-20	PD-1/PD-L1	Cancer
PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4 ^[1].

HY-101097A

PD-1-IN-17 TFA	PD-1/PD-L1	Cancer
PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM ^[1].

HY-159892

PD-1/PD-L1-IN-54	PD-1/PD-L1 IFNAR Interleukin Related PI3K Akt	Cancer
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic *PD-1/PD-L1* inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8 ⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1 ^[1].

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity ^[1].

HY-144447

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases ^[1].

HY-158052

PD-1/PD-L1 antagonist 1	PD-1/PD-L1	Cancer
PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC₅₀ of 23.78 nM ^[1].

HY-163307

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity ^[1].

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity ^[1].

HY-144443

PD-1/PD-L1-IN-16	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch ^[1].

HY-144442

PD-1/PD-L1-IN-15	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch ^[1].

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between **PD-1 and PD-L1, with an IC₅₀** of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% ^[1].

HY-132192

PD-1/PD-L1-IN-9 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model ^[1].

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-163534

PD-1/PD-L1-IN-43	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and *PD-L1. PD-1*/PD-L1-IN-43 can be used in anti-tumor studies ^[1].

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases ^[1].

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-153064

MAX-10181 pd-1/pd-L1-IN-30	PD-1/PD-L1	Cancer
MAX-10181 (PD-1/PD-L1-IN-30) is a *PD-1/PD-L1* binding inhibitor, with an IC₅₀ value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases ^[1].

HY-129172

PD-1/PD-L1-IN 5 TFA	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 TFA is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM ^[1].

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1*/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice ^[1].

HY-154869

PD-1/PD-L1-IN-34	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits *PD-1/PD-L1* interaction (IC₅₀=0.029 μM), with a selected binding affinity with PD-L1 (K_D=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment ^[1].

HY-138407

Evixapodlin GS-4224; pd-1/pd-L1-IN 7	PD-1/PD-L1 HBV	Infection Cancer
Evixapodlin (GS-4224) is a *human PD-1/PD-L1 protein/protein interaction* inhibitor with an IC₅₀ of 0.213 nM. Evixapodlin has anticancer and antiviral functions ^[1].

HY-157055

PD-1-IN-25	PD-1/PD-L1	Cancer
PD-1-IN-25 (compound 43) is a potent PD-1/PD-L1 interaction inhibitor with an IC50 value of 10.2 nM in the HTRF assay. PD-1-IN-25 can promote CD8+ T cell activation through inhibiting PD-1/PD-L1 cellular signaling. PD-1-IN-25 delays the tumor growth ^[1].

HY-128605

PD-1-IN-22	PD-1/PD-L1	Cancer
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM ^[1].

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent *PD-1/PD-L1* interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model ^[1].

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145770

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-129172A

PD-1/PD-L1-IN 5	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM ^[1].

HY-145772

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145773

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-145768

PD-1/PD-L1-IN-18	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC₅₀ of 1.054 μM. Antitumor Activity ^[1].

HY-163844

PD-1/PD-L1-IN-49	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC₅₀ of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint ^[1].

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 ^[1].

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer ^[1].

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy ^[1].

HY-168080

PD-1/PD-L1-IN-51	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-51 (Compound III-4) is a *PD-1/PD-L1* inhibitor (IC₅₀: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity ^[1].

HY-157811

PD-1/PD-L1-IN-40	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer ^[1].

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent *PD-1/PD-L1* inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs ^[1].

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion ^[1].

HY-163837

PD-1/PD-L1-IN-48	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research ^[1].

HY-169190

PD-1/PD-L1-IN-53	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-53 (compound B3) is an inhibitor targeting *PD-1/PD-L1* and VISTA signaling pathways. PD-1/PD-L1-IN-53 can be used in anti-cancer research ^[1].

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy ^[1].

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases ^[1].

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P1812

AUNP-12 3 Publications Verification NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P1812A

AUNP-12 TFA 3 Publications Verification NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) ^[1].

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model ^[1].

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1].

HY-P10908

H-20	PD-1/PD-L1	Others
H-20 is a *PD-1* agonist. H-20 can be used in the research of chronic pain ^[1].

HY-P10424

OPBP-1	PD-1/PD-L1	Cancer
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind *PD-L1* protein, significantly block the interaction between *PD-1* and *PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP*-1 can be used in cancer immunotherapy research ^[1].

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy ^[1].

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
PL120131 is a *PD-1/PD-L1* inhibitory peptide that can interfere with the interaction of *PD-1/PD-L1* by binding to *PD-1. PL120131 is capable of inhibiting the PD-1*-mediated apoptotic signaling pathway, protecting Jurkat cells and primary lymphocytes from apoptosis. PL120131 aids in the antitumor activity of cytotoxic T lymphocytes (CTLs) ^[1].

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein inhibitor with a K_d** value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 ^[1].

HY-P10375

BMS-986189	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC₅₀ of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 ^[1] .

HY-P10091

CD24/Siglec-10 blocking peptide, CSBP	PD-1/PD-L1	Cancer
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell ^[1].

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs ^[1].

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the?PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P99144A

*Anti-Mouse PD-1* Antibody (S-5001)**	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse *PD-1* IgG1 antibody inhibitor.

HY-P990824

*Anti-Mouse PD-1* Antibody (J43)**	PD-1/PD-L1	Others
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to *PD-1. The recommend isotype control of Anti-Mouse PD-1* Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-P99144

*Anti-Mouse PD-1* Antibody (RMP1-14)** 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody is an anti-mouse *PD-1* IgG2a antibody inhibitor.

HY-P9902A

*Pembrolizumab (anti-PD-1)* 2 Publications Verification MK-3475 (anti-pd-1); Lambrolizumab (anti-pd-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* ^[1] .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity ^[1].

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases ^[1].

HY-P991078

*Anti-Mouse PD-1* (LALA-PG) Antibody (RMP1-14)**	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P991079

*Anti-Mouse PD-1* Antibody (D265A) Antibody (RMP1-14)**	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P99048A

*Sintilimab (Anti-PD-1)* IBI308 (Anti-pd-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[1] .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Others Cancer
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells ^[1].

HY-P99106

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to *PD-1* ^[1] .

HY-P99457

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against *PD-1* ^[1].

HY-P99887

Pimivalimab JTX-4014	PD-1/PD-L1	Cancer
Pimivalimab (JTX-4014) is a *PD-1* inhibitor. Pimivalimab can be used for the research of solid tumor ^[1].

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and *PD-1* and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity ^[1].

HY-P9902

Pembrolizumab 10+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99619

Finotonlimab SCT-I10A	PD-1/PD-L1	Cancer
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research ^[1].

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research ^[1] .

HY-P991147

Ledostomig	PD-1/PD-L1	Cancer
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers ^[1].

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301) is a high-affinity, fully human *PD-L1*-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy ^[1].

HY-P991122

Besufetamig	PD-1/PD-L1 CD3	Inflammation/Immunology Cancer
Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers ^[1].

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a *humanized anti-PD-L1 antibody* (IgG1κ type). Tagitanlimab selectively blocks the interaction of *PD-L1* and *PD-1*. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) ^[1] .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is a selective, recombinant, humanized monoclonal antibody against *PD-1. Toripalimab is able to bind to PD-1* and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma ^[1].

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block *PD-1* and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) ^[1] .

HY-P9972

Spartalizumab pdR001	PD-1/PD-L1	Cancer
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds *PD-1* with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) ^[1].

HY-P99687

Latikafusp AMG 256	PD-1/PD-L1	Cancer
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research ^[1] .Latikafusp may lead to the development of immunogenicity-mediated responses .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[1] .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation ^[1].

HY-P990072

Lipustobart LZM-009	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-PDCD1 *(programmed cell death 1, PD1, PD-1, CD279)* humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity ^[1].

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^[1] .

HY-P99639

Geptanolimab Genolimzumab; APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer ^[1].

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo ^[1].

HY-P991085

HX009	PD-1/PD-L1	Cancer
HX009 is a bispecific antibody targeting *PD1* and CD47, but with weakened CD47 binding. HX009 blocks the functional of PD1/CD47. HX009 can be used for the study of non-Hodgkin’s lymphoma (NHL) ^[1].

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis ^[1] .

HY-P99957

Zeluvalimab AMG-404	PD-1/PD-L1	Cancer
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer ^[1].

HY-P99679

Izuralimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 ^[1].

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors ^[1].

HY-P9903

Nivolumab Maximum Cited Publications 21 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma ^[1] .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma ^[1] .

HY-P99641

Gilvetmab	PD-1/PD-L1	Cancer
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. Gilvetmab blocks the interaction between PD-1 and its ligand PD-L1/L2. Gilvetmab can be used in malignant melanoma and mast cell tumor research ^[1] .

HY-P9993

Peresolimab 1 Publications Verification LY-3462817	PD-1/PD-L1	Inflammation/Immunology
Peresolimab is a humanized IgG1-κ antibody targeting to *PD-1*. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. Peresolimab can be used in research of rheumatoid arthritis ^[1] .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo ^[1].

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively ^[1].

HY-P99100

Visugromab 1 Publications Verification CTL-002	PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors ^[1].

HY-P990486

*Anti-PDCD1/PD-1/CD279 Antibody*	PD-1/PD-L1	Inflammation/Immunology
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets *PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1*/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P99117

Cadonilimab AK104	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Cadonilimab (AK104) is a humanized tetravalent *IgG1* bispecific antibody targeting *PD1/CTLA4. Cadonilimab blocks both PD-1* and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) ^[1] .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to *PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1*. Garivulimab has antitumor activity ^[1].

HY-P9919

Durvalumab 5 Publications Verification MEDI 4736	PD-1/PD-L1	Cancer
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody ^[1]. Durvalumab (MEDI4736) completely blocks the binding of *PD-L1* to both *PD-1* and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively .

HY-P990169

*Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)*	PD-1/PD-L1	Others
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can be used in WB and FC experiments in the context of human and mouse.

HY-P9919A

Durvalumab (anti-PD-L1) 5 Publications Verification MEDI 4736 (anti-pd-L1)	PD-1/PD-L1	Cancer
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks *PD-L1* binding to *PD-1* and CD80, IC₅₀ are 0.1 and 0.04 nM respectively, has anti-tumor activity ^[1] .

Cat. No.	Product Name		Classification

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer ^[1].

HY-169392

D5B		DBCO
D5B is a potent and selective *PD-L1* inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

pd-1

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products